Charles Zhou
Stock Analyst at Guggenheim
(2.81)
# 1,984
Out of 5,102 analysts
11
Total ratings
62.5%
Success rate
26.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Buy | $17 → $20 | $40.04 | -50.05% | 2 | Aug 25, 2025 | |
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $172.77 | -21.28% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $24.94 | -35.85% | 1 | Mar 8, 2023 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.41 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.25 | +4,380.00% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $2.14 | +2,049.53% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $3.96 | - | 2 | Jan 22, 2020 |
Cogent Biosciences
Aug 25, 2025
Maintains: Buy
Price Target: $17 → $20
Current: $40.04
Upside: -50.05%
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $172.77
Upside: -21.28%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $24.94
Upside: -35.85%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.41
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.25
Upside: +4,380.00%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $2.14
Upside: +2,049.53%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.96
Upside: -